Clinical Characteristics of Breast Cancer Patients in Korea in Year 2000

e13671 Background: A 70-gene prognosis-signature, known as MammaPrint (MP), is validated as a good predictor of recurrence in patients with ER+/HER2- early stage breast cancer in Europe and America. Previous studies on Japanese and Korean breast cancer patients showed that the proportion of MP Low-Risk tumours is significantly lower than the percentage which reported in previous studies. Here we use MammaPrint to determine the gene profiles of breast cancer tumours from Chinese patients and investigate the test’s potential clinical applications. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumour samples or fresh tumour samples from 594 eligible breast cancer patients were collected from 97 hospitals in China. Tumor RNAs were isolated from samples and analyzed using RNA sequencing technology. Clinical risk was categorized based on the Adjuvant! algorithm as used in the MINDACT trial. Concordance between risk predicted by the MammaPrint and clinical characteristics were evaluated. We also analyzed the clinical-pathology features of patients and compared them to previous studies. Results: Overall, 315 patients were categorized as clinical high risk (182 were MP Low-Risk and 133 MP High-Risk), while 279 patients were categorized as clinical low risk (203 were MP Low-Risk and 76 MP High-Risk). The concordance rate between risk predicted by the MammaPrint and clinical characteristics was 56.57%. Among the clinical-pathology features, age, ER/PR/HER2 status, tumour grade and tumour size were significantly related to the genomic risk (p = 0.009, 0.003, < 0.001, 0.001, < 0.001, and 0.007 respectively). Conclusions: The proportion of MP Low-Risk tumours was 64.81%, which is similar to previous validated studies in Europe and America. Of the patients that were clinical high risk, 58% was categorized as MP Low-Risk, and this group of patients may have limited benefit from chemotherapy. Our results indicate that MammaPrint is applicable to Chinese patients and has potential value in clinical practice to avoid over-treatment.

Download Full-text

The Clinical Characteristics and Prognosis of Chinese Early Stage Breast Cancer Patients: A Retrospective Study

The Breast Journal ◽

10.1111/j.1524-4741.2010.00903.x ◽

2010 ◽

Vol 16 (3) ◽

pp. 331-333 ◽

Cited By ~ 7

Author(s):

Wen L Lu ◽

Hai X Li ◽

Bi Y. Qian ◽

Yuan Wang ◽

Liesbeth Jansen ◽

...

Keyword(s):

Breast Cancer ◽

Retrospective Study ◽

Cancer Patients ◽

Clinical Characteristics ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Breast Cancer Patients

Download Full-text

Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis ◽

10.1016/j.mrfmmm.2008.09.014 ◽

2008 ◽

Vol 648 (1-2) ◽

pp. 65-72 ◽

Cited By ~ 66

Author(s):

Ewelina Synowiec ◽

Joanna Stefanska ◽

Zbigniew Morawiec ◽

Janusz Blasiak ◽

Katarzyna Wozniak

Keyword(s):

Breast Cancer ◽

Dna Damage ◽

Dna Repair ◽

Cancer Patients ◽

Clinical Characteristics ◽

Dna Repair Genes ◽

Breast Cancer Patients ◽

Repair Genes

Download Full-text

A comparative study of the clinical characteristics and outcomes of HR-positive HER2-negative breast cancer patients over and under 65 years old

Korean Journal of Clinical Oncology ◽

10.14216/kjco.21001 ◽

2021 ◽

Vol 17 (1) ◽

pp. 1-7

Author(s):

Chang Shin Jung ◽

Youn Joo Jung ◽

Dong Il Kim ◽

Seungju Lee ◽

Seok Kyung Kang ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Clinical Characteristics ◽

Age Groups ◽

Older Age ◽

Age Group ◽

Breast Cancer Patients ◽

Her2 Breast Cancer ◽

Surgical Methods ◽

Two Age Groups

Purpose: The purpose of this study was to compare the clinical characteristics and outcomes of hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2–) breast cancer among elderly patients (over 65 years old) and younger patients.Methods: This was a retrospective cohort study of 328 patients who were treated for breast cancer at Pusan National University Yangsan Hospital between January 2009 and December 2014. Tumor characteristics, surgical methods, and survival outcomes were compared between the two age groups (<65 and ≥65 years old). Kaplan-Meier curves for disease-free survival (DFS) and overall survival (OS) were also constructed according to the age groups.Results: Among the 328 patients with HR+ HER2– breast cancer, 184 (56.1%) were <65 years old and 144 (43.9%) were ≥65 years old. Breast cancer stages were similar between the two age groups, but the older patients were treated less often with chemotherapy (81% vs. 66%, P=0.002). During the follow-up period, 17 deaths and 36 cases of recurrence or metastasis were reported. There was no difference in DFS between the two groups (P=0.840); however, the OS of the older age group was significantly lower than that of the younger age group (P=0.015).Conclusion: This study suggested that HR+ HER2– breast cancer patients belonging to the two age groups had no significant difference in DFS. However, older age is an independent factor affecting OS rate. Therefore, even if patients are old, but their physical condition is satisfactory, standard and active treatment may be necessary, similar to that given to younger patients.

Download Full-text

A comparative study of the clinical characteristics of breast cancer patients less than 35 years old and older patients

Korean Journal of Clinical Oncology ◽

10.14216/kjco.18001 ◽

2018 ◽

Vol 14 (1) ◽

pp. 1-7

Author(s):

Tae Sik Hwang ◽

Ah Rem Jeong ◽

Joung Won Na ◽

Yun Yeong Kim ◽

Joon-Hyop Lee ◽

...

Keyword(s):

Breast Cancer ◽

Comparative Study ◽

Cancer Patients ◽

Older Patients ◽

Clinical Characteristics ◽

Breast Cancer Patients

Download Full-text

Analysis of clinical characteristics in breast cancer patients with the Japanese founder mutation of BRCA1 L63X.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.28_suppl.22 ◽

2015 ◽

Vol 33 (28_suppl) ◽

pp. 22-22

Author(s):

Reiko Yoshida ◽

Mayuko Inuzuka ◽

Tomoko Watanabe ◽

Junko Yotsumoto ◽

Takashi Kuwayama ◽

...

Keyword(s):

Breast Cancer ◽

Ovarian Cancer ◽

Cancer Patients ◽

Clinical Characteristics ◽

Founder Mutation ◽

Breast Cancers ◽

Pathological Features ◽

Breast Cancer Patients ◽

Breast And Ovarian Cancer ◽

Brca1 Mutations

22 Background: Hereditary breast and ovarian cancer (HBOC) is a high-penetrance inherited disease, and founder mutation has been reported in the West. However, there are yet no reports of founder mutation of HBOC on breast cancer in the Japanese population. In this study, we report the breast cancer clinical characteristics of L63X, which is one of the founder mutations in BRCA1 in the Japanese population. Methods: Data on 223 affected breast cancer patients (28 BRCA1 carriers, 19 BRCA2 carriers, and 176 non-carriers) were collected at Showa University in Tokyo from September 2010 to June 2015. In 22 independent mutations of BRCA1, the L63X mutation was detected in 9 patients. Data regarding the age of breast cancer onset, pathological features, clinical features, and family history were collected. Results: The age of onset was no significant differences between the L63X mutation and other BRCA1 mutations (39.7 vs. 38.5years). The proportion of triple negative breast cancer patients was 87.5% in the L63X mutation carriers and 89.5% in other BRCA1 mutation carriers. No patients of the L63X affected bilateral breast cancers. On the other hand, 36.7% of other BRCA1mutations affected bilateral breast cancers. There was no significant difference in pathological features (intrinsic subtype, nuclear grade and ki-67 index). The L63X carriers tended to have a family history of breast cancers. All L63X mutations were detected in the Eastern part of Japan. Conclusions: The breast cancer clinical characteristics of L63X might be considered no different from other types of BRCA1 mutations. Recently, it has been reported that breast and ovarian cancer risks varied according to the type and location of BRCA1/2 mutations. L63X mutation is located in the breast cancer cluster region in BRCA1. Further investigation is necessary for appropriate validation and accumulation of data.

Download Full-text